- Home
- NPFD vs FDMT Comparison
NPFD vs FDMT Comparison
Compare NPFD & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NPFD | FDMT |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 474.6M | 513.6M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NPFD | FDMT |
|---|---|---|
| Price | $19.15 | $8.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $34.13 |
| AVG Volume (30 Days) | 65.9K | ★ 691.6K |
| Earning Date | 01-01-0001 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $37,000.00 |
| Revenue This Year | N/A | $21,227.03 |
| Revenue Next Year | N/A | $161.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.79 | $2.24 |
| 52 Week High | $20.12 | $12.34 |
Technical Indicators
Market Signals| Indicator | NPFD | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 31.78 | 44.55 |
| Support Level | $18.93 | $8.11 |
| Resistance Level | $19.29 | $8.80 |
| Average True Range (ATR) | 0.19 | 0.56 |
| MACD | -0.08 | -0.12 |
| Stochastic Oscillator | 19.59 | 17.03 |
Price Performance
Historical ComparisonAbout NPFD Nuveen Variable Rate Preferred & Income Fund
Nuveen Variable Rate Preferred&Income is a diversified, closed-end management investment company. Its investment objective is to provide a high level of current income and total return. The fund invests a majority of its assets in variable-rate preferred securities and other variable-rate income-producing securities. The rest of its investments can be made in contingent capital securities or contingent convertible securities, convertible securities, corporate debt securities, U.S. government securities, residential and commercial mortgage-backed securities, fixed-rate preferred securities, senior loans and loan participations and assignments, sovereign debt instruments, debt securities issued by supranational agencies, and/or taxable and tax-exempt municipal bonds.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.